(Total Views: 420)
Posted On: 10/31/2019 10:47:40 AM
Post# of 36568
https://www.businesswire.com/news/home/201812...-FDA-Phase
Doc can explain this better than me. If AE 37 improves Keytruda's efficacy beyond its present incredible success, partnership, licensing, maybe even sale of AE 37 are on the table. This is just one of those initiatives with tremendous "potential" for making GNBT profitable.
We have no way of knowing for sure, but I have not seen an OTC equity with as many ponies in the stable as Generex. For sure Generex is not a "one-trick pony." Any cash coming into the company can then be used to fund other phases of Generex' development.
Doc can explain this better than me. If AE 37 improves Keytruda's efficacy beyond its present incredible success, partnership, licensing, maybe even sale of AE 37 are on the table. This is just one of those initiatives with tremendous "potential" for making GNBT profitable.
We have no way of knowing for sure, but I have not seen an OTC equity with as many ponies in the stable as Generex. For sure Generex is not a "one-trick pony." Any cash coming into the company can then be used to fund other phases of Generex' development.
(2)
(0)
